Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD10 | Q9NUJ1 | 1/20 | 0.75 |
| ▸ | EIF4A1 | P60842 | 17/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17396593 | 1.00 | ABHD10 (0.75) | ABHD10EIF4A1CYP3A4HIF1ANFKB1 | |
| SCHEMBL17396619 | 0.91 | ABHD10 (0.63) | ABHD10EIF4A1CYP3A4HIF1ANFKB1 | |
| SCHEMBL17396618 | 0.91 | ABHD10 (0.63) | ABHD10EIF4A1CYP3A4HIF1ANFKB1 | |
| SCHEMBL18836365 | 0.91 | ABHD10 (0.62) | ABHD10EIF4A1CYP3A4HIF1ANFKB1 | |
| SCHEMBL17414029 | 0.91 | ABHD10 (0.62) | ABHD10EIF4A1CYP3A4HIF1ANFKB1 | |
| SCHEMBL29532363 | 0.91 | ABHD10 (0.62) | ABHD10EIF4A1CYP3A4HIF1ANFKB1 | |
| SCHEMBL17396547 | 0.90 | ABHD10 (0.68) | ABHD10EIF4A1CYP3A4HIF1ANFKB1 | |
| SCHEMBL29532358 | 0.90 | ABHD10 (0.68) | ABHD10EIF4A1CYP3A4HIF1ANFKB1 | |
| SCHEMBL17396545 | 0.90 | ABHD10 (0.68) | ABHD10EIF4A1CYP3A4HIF1ANFKB1 | |
| SCHEMBL17396562 | 0.90 | ABHD10 (0.61) | ABHD10EIF4A1CYP3A4HIF1ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998257-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998257-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3418273-B1 | FLAVAGLINE DERIVATIVES | PF MEDICAMENT (FR) | 2022-01-12 | — | — | EP | disclosed |
| EP-3418273-B1 | FLAVAGLINE DERIVATIVES | PF MEDICAMENT (FR) | 2022-01-12 | — | — | EP | disclosed |
| US-10519125-B2 | Flavagline derivatives | PIERRE FABRE MEDICAMENT (FR) | 2019-12-31 | — | — | US | disclosed |
| US-10519125-B2 | Flavagline derivatives | PIERRE FABRE MEDICAMENT (FR) | 2019-12-31 | — | — | US | disclosed |
| EP-3418273-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2018-12-26 | — | — | EP | disclosed |
| EP-3164393-B1 | FLAVAGLINE DERIVATIVES | PF MEDICAMENT (FR) | 2018-09-19 | — | — | EP | disclosed |
| US-20180086729-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2018-03-29 | — | — | US | disclosed |
| US-20180086729-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2018-03-29 | — | — | US | disclosed |
| US-20180086729-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2018-03-29 | — | — | US | disclosed |
| US-20170137400-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2017-05-18 | — | — | US | disclosed |
| US-20170137400-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2017-05-18 | — | — | US | disclosed |
| US-20170137400-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2017-05-18 | — | — | US | disclosed |
| EP-3164393-A1 | FLAVAGLINE DERIVATIVES | Pierre Fabre Médicament (FR) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001441-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016001441-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137400-A1 | FLAVAGLINE DERIVATIVES | GCG, GCGR, KRAS | ABHD10 2858/4885EIF4A1 2949/4885CYP3A4 50/4885 |
| US-20180086729-A1 | FLAVAGLINE DERIVATIVES | GCG, GCGR, KRAS | ABHD10 2858/4885EIF4A1 2949/4885CYP3A4 50/4885 |
| US-10519125-B2 | Flavagline derivatives | GCG, GCGR, KRAS | ABHD10 2858/4885EIF4A1 2949/4885CYP3A4 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.